Published in Neuro-Oncology on July 4, 2024, the final analysis from the phase II TUXEDO-1 trial confirms the strong intracranial and systemic efficacy of trastuzumab deruxtecan (T-DXd) in patients with HER2-positive breast cancer and active brain metastases. With a median follow-up of 26.5 months, median progression-free survival reached 21 months, and overall survival was not yet reached at the time of reporting. Importantly, quality of life was maintained throughout treatment, and no new safety signals were observed. The most common grade 3 adverse event was fatigue, seen in 20% of patients. These results further support the role of antibody-drug conjugates as a systemic treatment strategy in patients with active brain metastases, in line with data from pivotal trials.
Full article: https://lnkd.in/dGmgRwZE
